BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed use of a single dose of investigational REGEN-COV® (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals.

HAPPE Spine , an emerging leader in the development of next generation orthopedic and spinal implants enabled by the HAPPE ™ material platform, announces that it has closed on a $3.35 million Series A capital raise.

Pops announces clearance from Australia’s regulatory body, the Therapeutic Goods Administration, and it’s first commercial user in Australia. Pops, a digital health company for diabetes and related chronic conditions, is already commercialized in the United States.

NeoImmuneTech, Inc. today announced that the first patient has been dosed in a Phase 2 study evaluating NT-I7

Soligenix, Inc. announced today that it has been granted a Pediatric Investigation Plan (PIP) product-specific waiver from the Medicines and Healthcare products Regulatory Agency (MHRA) for HyBryte™ (SGX301 or synthetic hypericin), which has successfully concluded a Phase 3 pivotal clinical study for the treatment of early stage cutaneous T-cell lymphoma (CTCL).

Reata Pharmaceuticals, Inc. today announced financial results for the quarter ended September 30, 2021, and provided an update on the Company’s business operations and clinical development programs.

QuantuMDx Group Limited, announces it has secured a £15 million equity investment from Vita Spring IVD Fund, L.P., a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.

First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor –

Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference taking place on November 15-17, 2021.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2021.